Telemedicine-supported Management for Acute Ischemic Stroke
TOGETHER
1 other identifier
interventional
2,400
1 country
1
Brief Summary
Telemedicine-supported stroke care can provide standardized guidance to hospitals and regions with limited medical resources, thereby improving treatment outcomes for stroke patients in these areas. While this approach has been widely adopted in many developed countries, its efficacy in guiding basic-level hospitals to manage acute ischemic stroke requires further investigation through large-scale, high-quality studies. This study focused on patients with acute ischemic stroke who sought treatment at basic-level hospitals, aiming to investigate the efficacy and safety of treating acute ischemic stroke with telemedicine-supported management. Hospitals assigned to the experimental group received remote consultation guidance, quality control and professional training from expert teams at leading stroke centers, China National Center for Neurological Disorders. Hospitals in the control group did not receive telemedicine-supported management.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 2, 2025
CompletedFirst Posted
Study publicly available on registry
December 24, 2025
CompletedStudy Start
First participant enrolled
February 2, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
February 3, 2026
November 1, 2025
1.3 years
December 2, 2025
February 2, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Proportion of patients with mRS scores of 0-1
90 days
Secondary Outcomes (4)
Intravenous thrombolysis rate
4.5 hours
mRS score
90 days
Door-to-(thrombolysis)needle-time
4.5 hours
Rate of endovascular therapy receipt among eligible patients
24 hours
Other Outcomes (3)
Proportion of sICH
Within 36 hours of thrombolysis
Proportion of any type of ICH
Within 36 hours of thrombolysis
All-cause mortality rate
90 days
Study Arms (2)
Telemedicine-Supported Group
EXPERIMENTALReceive remote guidance from expert stroke centers for treatment of patients with intravenous thrombolysis, along with quality control for standardized workflow support, and professional training.
Standard Treatment Group without Telemedicine-Supported Management
NO INTERVENTIONControl-group patients will receive routine stroke care at their primary care hospitals, with no remote consultation, study-related quality control, or extra training. Care will follow the hospitals' usual protocols, including emergency assessment, neurological evaluation, imaging, and intravenous thrombolysis. Hospitals may continue their regular stroke-related training during the study to reflect real-world practice.
Interventions
Receive round-the-clock 7×24h remote consultation guidance from expert teams at leading stroke centers, covering patient triage and initial assessment, thrombolysis decision-making, and treatment guidance. Undergo quality control for standardized workflow implementation, and professional training.
Eligibility Criteria
You may qualify if:
- Basic-level hospitals in China (Definition: Hospitals classified as secondary-level (Grade II) or below under China's Hospital Grading Management Standards, or hospitals located in counties/county-level cities).
- Equipped with an emergency department and neurology ward capable of admitting stroke patients.
- Equipped with CT and/or MRI capable of diagnosing AIS.
- Equipped with intravenous thrombolytic drugs for acute ischemic stroke.
- Age ≥ 18 years.
- Diagnosed with acute ischemic stroke.
- CT/MRI confirms absence of intracerebral hemorrhage.
- Onset of stroke symptoms ≤ 4.5 hours.
- pre-stroke mRS score ≤1.
- Informed consent obtained from patient or their legal representative.
You may not qualify if:
- Admitting fewer than 10 patients with acute ischemic stroke per month.
- Currently participating in other clinical trials that may interfere with this trial.
- Presence of contraindications for intravenous thrombolysis according to AHA/ASA guidelines
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Xuanwu Hospital
Beijing, Beijing Municipality, 100053, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Neurology, Xuanwu Hospital, Capital Medical University
Study Record Dates
First Submitted
December 2, 2025
First Posted
December 24, 2025
Study Start
February 2, 2026
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
February 3, 2026
Record last verified: 2025-11